Quantum Capital Management LLC NJ Cuts Stake in IDEXX Laboratories, Inc. $IDXX

Quantum Capital Management LLC NJ lessened its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.8% during the fourth quarter, Holdings Channel.com reports. The fund owned 76,446 shares of the company’s stock after selling 1,379 shares during the period. IDEXX Laboratories accounts for 6.0% of Quantum Capital Management LLC NJ’s holdings, making the stock its 8th largest holding. Quantum Capital Management LLC NJ’s holdings in IDEXX Laboratories were worth $51,718,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Virtus Advisers LLC bought a new stake in IDEXX Laboratories in the 3rd quarter worth $26,000. Park Place Capital Corp bought a new stake in shares of IDEXX Laboratories during the 4th quarter valued at about $29,000. WealthCollab LLC bought a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at about $30,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at about $36,000. Finally, Mowery & Schoenfeld Wealth Management LLC boosted its stake in shares of IDEXX Laboratories by 58.8% during the 4th quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock valued at $37,000 after purchasing an additional 20 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Trading Up 0.5%

Shares of NASDAQ IDXX opened at $560.88 on Friday. IDEXX Laboratories, Inc. has a 1 year low of $506.91 and a 1 year high of $769.98. The stock has a market cap of $44.24 billion, a P/E ratio of 41.30, a price-to-earnings-growth ratio of 3.05 and a beta of 1.55. The firm has a 50-day moving average of $563.06 and a 200 day moving average of $627.69. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.41 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same period in the previous year, the company earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, sell-side analysts expect that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. UBS Group cut their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Wall Street Zen raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday. Citigroup started coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target for the company. Finally, Stifel Nicolaus lowered their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Seven research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.